Specialized Research

PNC-27

Also known as: Peptídeo p53

Overview

Research peptide derived from the p53 tumor suppressor protein, designed to selectively bind to HDM-2 protein (human MDM-2) overexpressed on cancer cell membranes. Induces selective lysis of tumor cells without affecting normal cells. Used exclusively in oncology research contexts.

Hybrid peptide — sequence derived from p53 with HDM-2 binding domain, contains modified amino acids

Half-life

~1-3 hours

Administration Route

Subcutaneous

Category

Specialized Research

Mechanism of Action

  • Selective binding to HDM-2 expressed on cancer cell membranes
  • Induction of selective tumor cell lysis via membrane pore formation
  • Preservation of normal cells that do not express HDM-2 on the surface
  • Activation of apoptotic pathways in neoplastic cells

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 100-500 mcg per administration (research context)
Frequency Per research protocol
Timing Per protocol
Duration Variable — defined by research protocol

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Local inflammation
  • Transient fever

Presentations & Preparation

Vials of PNC-27 found in the research market:

5 mg10 mg15 mg20 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: -20°C for long-term storage
  • Reconstituted: Refrigerated 2-8°C (use within a few days)
  • Protect from direct light
  • Do not freeze after reconstitution
  • Maintain strict cold chain
Reconstitution Calculator

Scientific Studies

Published studies on PNC-27.

2010 · Proc Natl Acad Sci U S A

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes

Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, Patel H, Oxbury W, Brandt-Rauf P, Zenilman ME, Michl J, Pincus MR

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily